These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31205007)

  • 1. Long Term Response to Levodopa in Parkinson's Disease.
    Gupta HV; Lyons KE; Wachter N; Pahwa R
    J Parkinsons Dis; 2019; 9(3):525-529. PubMed ID: 31205007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subthalamic deep brain stimulation and levodopa in Parkinson's disease: a meta-analysis of combined effects.
    Vizcarra JA; Situ-Kcomt M; Artusi CA; Duker AP; Lopiano L; Okun MS; Espay AJ; Merola A
    J Neurol; 2019 Feb; 266(2):289-297. PubMed ID: 29909467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
    Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
    PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa.
    Cilia R; Cereda E; Akpalu A; Sarfo FS; Cham M; Laryea R; Obese V; Oppon K; Del Sorbo F; Bonvegna S; Zecchinelli AL; Pezzoli G
    Brain; 2020 Aug; 143(8):2490-2501. PubMed ID: 32844196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.
    Rosqvist K; Horne M; Hagell P; Iwarsson S; Nilsson MH; Odin P
    J Parkinsons Dis; 2018; 8(1):59-70. PubMed ID: 29480220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-duration response to levodopa in patients with advanced Parkinson disease treated with subthalamic deep brain stimulation.
    Wider C; Russmann H; Villemure JG; Robert B; Bogousslavsky J; Burkhard PR; Vingerhoets FJ
    Arch Neurol; 2006 Jul; 63(7):951-5. PubMed ID: 16831963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced therapies in Parkinson's disease: Long-term retrospective study.
    Merola A; Espay AJ; Romagnolo A; Bernardini A; Rizzi L; Rosso M; Espay KJ; Zibetti M; Lanotte M; Lopiano L
    Parkinsonism Relat Disord; 2016 Aug; 29():104-8. PubMed ID: 27215392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ropinirole: a review of its use in the management of Parkinson's disease.
    Matheson AJ; Spencer CM
    Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson's disease.
    Ostrem JL; Ziman N; Galifianakis NB; Starr PA; Luciano MS; Katz M; Racine CA; Martin AJ; Markun LC; Larson PS
    J Neurosurg; 2016 Apr; 124(4):908-16. PubMed ID: 26495947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study.
    Lopiano L; Modugno N; Marano P; Sensi M; Meco G; Cannas A; Gusmaroli G; Tamma F; Mancini F; Quatrale R; Costanzo AM; Gualberti G; Melzi G; di Luzio Paparatti U; Antonini A
    Neurol Sci; 2016 Nov; 37(11):1785-1792. PubMed ID: 27421834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term impact on quality of life of subthalamic nucleus stimulation in Parkinson's disease.
    Lezcano E; Gómez-Esteban JC; Tijero B; Bilbao G; Lambarri I; Rodriguez O; Villoria R; Dolado A; Berganzo K; Molano A; de Gopegui ER; Pomposo I; Gabilondo I; Zarranz JJ
    J Neurol; 2016 May; 263(5):895-905. PubMed ID: 26964542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up.
    Rodriguez-Oroz MC; Obeso JA; Lang AE; Houeto JL; Pollak P; Rehncrona S; Kulisevsky J; Albanese A; Volkmann J; Hariz MI; Quinn NP; Speelman JD; Guridi J; Zamarbide I; Gironell A; Molet J; Pascual-Sedano B; Pidoux B; Bonnet AM; Agid Y; Xie J; Benabid AL; Lozano AM; Saint-Cyr J; Romito L; Contarino MF; Scerrati M; Fraix V; Van Blercom N
    Brain; 2005 Oct; 128(Pt 10):2240-9. PubMed ID: 15975946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.
    Cattaneo C; Jost WH; Bonizzoni E
    J Parkinsons Dis; 2020; 10(1):89-97. PubMed ID: 31594253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of depression and anxiety via patient-assessed tremor severity, not physician-reported motor symptom severity, in patients with Parkinson's disease or essential tremor who have undergone deep brain stimulation.
    Achey RL; Yamamoto E; Sexton D; Hammer C; Lee BS; Butler RS; Thompson NR; Nagel SJ; Machado AG; Lobel DA
    J Neurosurg; 2018 Dec; 129(6):1562-1571. PubMed ID: 29473781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inferring the long duration response to levodopa in Parkinson's disease.
    Nagao K; Ding C; Ganga G; Alty JE; Clissold BG; McColl CD; Reardon KA; Schiff M; Kempster PA
    Parkinsonism Relat Disord; 2019 Mar; 60():133-137. PubMed ID: 30217541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of elderly and young patient populations treated with deep brain stimulation for Parkinson's disease: long-term outcomes with up to 7 years of follow-up.
    Hanna JA; Scullen T; Kahn L; Mathkour M; Gouveia EE; Garces J; Evans LM; Lea G; Houghton DJ; Biro E; Bui CJ; Sulaiman OA; Smith RD
    J Neurosurg; 2019 Sep; 131(3):807-812. PubMed ID: 30265192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different effectiveness of subthalamic deep brain stimulation in Parkinson's disease: A comparative cohort study at 1 year and 5 years.
    Jiang JL; Chen SY; Hsieh TC; Lee CW; Lin SH; Tsai ST
    J Formos Med Assoc; 2015 Sep; 114(9):835-41. PubMed ID: 24103710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
    Juhász A; Aschermann Z; Ács P; Janszky J; Kovács M; Makkos A; Harmat M; Tényi D; Karádi K; Komoly S; Takáts A; Tóth A; Nagy H; Klivényi P; Dibó G; Dézsi L; Zádori D; Annus Á; Vécsei L; Varannai L; Kovács N
    Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duodenal Levodopa Infusion for Long-Term Deep Brain Stimulation-Refractory Symptoms in Advanced Parkinson Disease.
    Regidor I; Benita V; Del Álamo de Pedro M; Ley L; Martinez Castrillo JC
    Clin Neuropharmacol; 2017; 40(3):103-107. PubMed ID: 28452905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.